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Abstract
Objectives To describe the construction of the
international INTERGROWTH-21st Neurodevelopment
Assessment (INTER-NDA) standards for child development
at 2 years by reporting the cognitive, language, motor and
behaviour outcomes in optimally healthy and nourished
children in the INTERGROWTH-21st Project.
Design Population-based cohort study, the
INTERGROWTH-21st Project.
Setting Brazil, India, Italy, Kenya and the UK.
Participants 1181 children prospectively recruited from
early fetal life according to the prescriptive WHO approach,
and confirmed to be at low risk of adverse perinatal and
postnatal outcomes.
Primary measures Scaled INTER-NDA domain scores
for cognition, language, fine and gross motor skills and
behaviour; vision outcomes measured on the Cardiff tests;
attentional problems and emotional reactivity measured on
the respective subscales of the preschool Child Behaviour
Checklist; and the age of acquisition of the WHO gross
motor milestones.
Results Scaled INTER-NDA domain scores are presented
as centiles, which were constructed according to the
prescriptive WHO approach and excluded children born
preterm and those with significant postnatal/neurological
morbidity. For all domains, except negative behaviour,
higher scores reflect better outcomes and the threshold
for normality was defined as ≥10th centile. For the INTER-
NDA’s cognitive, fine motor, gross motor, language and
positive behaviour domains these are ≥38.5, ≥25.7, ≥51.7,
≥17.8 and ≥51.4, respectively. The threshold for normality
for the INTER-NDA’s negative behaviour domain is ≤50.0,
that is, ≤90th centile. At 22–30 months of age, the cohort
overlapped with the WHO motor milestone centiles,
showed low postnatal morbidity (<10%), and vision

Strengths and limitations of this study
►► The prescriptive WHO approach for developing bio-

logical standards was applied to a population-based
sample of healthy and well-nourished children from
Brazil, India, Italy, Kenya and the UK to construct
the INTERGROWTH-21st Project neurodevelopmental assessment (INTER-
NDA) standards for child
development.
►► Comprehensive health, growth and neurodevelopmental data were prospectively collected, from early
pregnancy to 2 years postbirth, providing a unique
opportunity to confirm the cohort’s health and nutritional status and to control for multiple risk factors
associated with suboptimal child development.
►► The INTER-
NDA is a mixed-
methodology, multidimensional, standardised measure of early child
development, which can be administered rapidly, by
non-specialists in high-income, middle-income and
low-income settings.
►► The INTER-NDA is a standardised screening assessment and does not provide a clinical diagnosis.
►► The age range of the INTER-NDA is 22–30 months
and limits its generalisability to other age groups.
outcomes, attentional problems and emotional reactivity
scores within the respective normative ranges.
Conclusions From this large, healthy and well-nourished,
international cohort, we have constructed, using the
WHO prescriptive methodology, international INTER-
NDA standards for child development at 2 years of age.
Standards, rather than references, are recommended
for population-level screening and the identification of
children at risk of adverse outcomes.
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Introduction
Approximately 250 million children under the age of 5
worldwide are at risk of not achieving their developmental
potential.1 Effective interventions are available but maximising their benefit at scale depends on identifying those
children at greatest need, preferably using standardised
methodology.2
At present, a multiplicity of methods is used to measure
neurodevelopment during early childhood (online
supplementary information S1).3 4 Many of these are
administered by specialist staff and were developed using
children from either high-income countries or specific
low-income and middle-income countries, each drawing
their normative sample (often country or region specific)
from the respective settings (online supplementary information S1 and S2).3 4 To our knowledge, none of these
tools commonly used to measure neurodevelopment in
early childhood, were based on children monitored from
fetal life and have adopted the prescriptive approach
recommended by the WHO for the development of international biological standards during the construction of
their norms.5 Instead, references have been commonly
used to assess the overall achievement of developmental
skills and track progress over time in both, groups of children and individuals. However, while references describe
how children, in a specific setting and time, have attained
certain milestones of interest, they do not describe how
children, in all settings, should develop. The importance of
this fundamental difference between references and standards was elegantly highlighted, in the context of skeletal
growth in young children, by WHO Multicentre Growth
Reference Study (MGRS), which resulted in the construction of prescriptive international standards for monitoring child growth.6 These WHO standards, describing
optimal growth from early pregnancy to 5 years of age,7
are now widely employed in clinical practice and used to
make comparisons across disparate populations.
The construction of international, prescriptive standards describing optimal neurodevelopment during early
childhood is challenging not least because of the technical and logistical difficulties of implementing comprehensive early child developmental assessments across
large international populations. To construct international standards of child development, in accordance with
WHO’s prescriptive methodology,5 four fundamental
methodological principles must be fulfilled: (1) the
normative sample should be selected using a ‘prescriptive’ approach, which includes consideration of key
factors known to be associated with poor developmental
outcomes during early childhood (online supplementary
information S2); (2) the conceptual framework must be
population-
based and international; (3) rigorous data
management, standardisation and quality control procedures must be included and (4) measurements must be
complemented by independent assessments of specific
functional and developmental domains (eg, tests of
vision) to confirm the prescriptive characteristics of the
sample. This rigorous approach is important because the
2

inclusion of inadequately nourished children, or those
with mild neurodevelopmental disturbances (NDDs), in
normative samples, can affect resultant thresholds. Moreover, the identification of children at risk of (even mild)
NDDs is essential because there is evidence to show that
very small developmental differences between individuals
during early childhood can result in marked discrepancies in mental and physical health, educational attainment, and social and economic outcomes during later
life.8 9
The INTERGROWTH-21st Project aimed to adopt
this WHO prescriptive approach in constructing international standards for child development measured
on a standardised, comprehensive assessment tool—
the INTERGROWTH-21st Neurodevelopment Assessment (INTER-
NDA)—at 2 years of age. Despite this
circumscribed age range, by leveraging on the INTERGROWTH-21st Project’s international cohort of mothers
and children, recruited specifically to be optimally
healthy and well-nourished throughout the duration of
pregnancy and confirmed, during the infant follow-up
component of the project, to be at low risk of adverse
birth, health and growth outcomes at birth, 1 and 2 years
of age, we were able to adopt the prescriptive approach
and methods recommended by the WHO MGRS in the
construction of the INTER-NDA standards of child development at 2 years of age. In the present study, we analysed cognitive, language, motor and behaviour outcomes
at 2 years of age, measured on the INTER-
NDA, for
healthy and well-nourished children from the INTERGROWTH-21st Project study sites in Brazil, India, Italy,
Kenya and the UK. We compared the vision, gross motor,
attentional problems and emotional reactivity profiles,
as well as growth and health outcomes, in these children to the corresponding norms for these independent
measures.
Methods
Study design and population
The INTERGROWTH-21st Project was a multicentre,
population-
based study conducted between 2009 and
2016, in eight delimited geographical areas worldwide:
the cities of Pelotas, Brazil; Turin, Italy; Muscat, Oman;
Oxford, UK; Seattle, USA; Shunyi County, a suburban
district of the Beijing municipality, China; the central
area of the city of Nagpur, Maharashtra, India and the
Parklands suburb of Nairobi, Kenya. A geographical area
was a complete city, or county, or part of a city with clear
political or geographical limits, located at an altitude
<1600 m, with low-
risk health indicators for perinatal
morbidity and mortality, in which women receiving antenatal care had plans to give birth within the area, that
had to be free or have low levels of major, known, non-
microbiological contamination.10 The primary aim of
the INTERGROWTH-21st Project was to study growth,
health and development from early fetal life to 2 years of
age in low-risk populations of mothers and children with
Fernandes M, et al. BMJ Open 2020;10:e035258. doi:10.1136/bmjopen-2019-035258
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optimal health and nutrition so as to produce prescriptive
standards of fetal growth, newborn size and early child
neurodevelopment to complement the existing WHO
Child Growth Standards.
The INTERGROWTH-21st Project recruited pregnant
women from the aforementioned populations, who met
the individual entry criteria of health, nutrition, education and socioeconomic position (online supplementary information S3).10 Standardised clinical care and
neonatal feeding practices were implemented based on
project protocols. The newborn cohort was followed up at
birth, 1 and 2 years of age and evaluated for growth, nutrition, health and the WHO gross motor milestones, using
standardised methodology and rigorous quality control
processes.11 They constitute the Infant Follow-up Study
(IFS) of the INTERGROWTH-21st Project. The baseline
characteristics of the full cohort and follow-
up methodology have been published elsewhere.11 The project
protocols are available at www.intergrowth21.org.uk.
Data collection and evaluation methods
All eligible children in five of the eight INTERGROWTH-21st Project study sites (the cities of Pelotas
(Brazil); Turin (Italy); Oxford (UK); Nagpur (India)
and the Parklands suburb of Nairobi (Kenya)), who had
contributed data towards the construction of the international Fetal Growth and Newborn Growth Standards,12 13
were invited to attend a comprehensive neurodevelopmental evaluation at the time of their second birthday.
This age was selected as it was found to be the earliest
at which: (1) neurodevelopment is not confounded by
transient neurological syndromes of prematurity and (2)
conventionally used developmental instruments, such as
the Bayley Scales of Infant Development (BSID), have
been found to possess an acceptable level of medium
and long-term predictive validity.14 The sites in China,
Oman and the USA did not participate because of logistical and administrative reasons, delays in the start of the
study and/or staff availability, all unrelated to the IFS’
main hypotheses (a comparison in the demographics,
and health and growth outcomes between these sites has
already been published).11
The evaluation consisted of (in order of administration): an assessment of vision (the Cardiff tests) an
assessment of cognition, motor skills, language skills
and behaviour (the INTER-NDA); caregiver reports of
attentional problems and emotional reactivity (the corresponding subscales of the preschool Child Behaviour
Checklist; CBCL); measurement of cortical auditory
processing (to a novelty odd-ball paradigm on a wireless,
gel-free electroencephalography system); measurement
of infant sleep (using actigraphy) and an assessment of
gross motor milestones (based on the WHO’s checklist).
Despite measuring cortical auditory processing and sleep
in our cohort, a description of the methods and results
relating to these technically complex outcomes are
beyond the scope of this paper. Moreover, as normative
values for cortical auditory evoked response potentials
Fernandes M, et al. BMJ Open 2020;10:e035258. doi:10.1136/bmjopen-2019-035258

and actigraphy data do not exist for children aged 2
years, the added value of these measures in confirming
the healthy and well-nourished status of the cohort is
uncertain. Information on the child’s health and nutritional status, and anthropometric measurements (weight,
length and head circumference), were also collected, at
the 2 year visit, according to the INTERGROWTH-21st
Project protocols.
A specially designed training programme for the neurodevelopmental evaluation was implemented at all sites
between 2012 and 2013.15 Staff administering the assessments were aware of the project’s general principles but
not the specific hypotheses being tested. They were also
unaware of individual children’s scores from their own
and other study sites.
Primary outcome measure: the INTER-NDA
The INTER-NDA is a comprehensive, rapid assessment
of cognition, (fine and gross) motor skills, language
and (positive and negative) behaviour for children aged
22–30 months (online supplementary information S4).15
Its 37 items are administered in approximately 15 min
using a combination of psychometric techniques (direct
administration, concurrent observation and caregiver
reports) to minimise risks of reporter and recall bias
commonly encountered in caregiver interviews3 while
acknowledging that children might perform differently
in artificial testing environments than in familiar settings.
Children’s performance on the INTER-NDA is scored
across a spectrum of abilities, rather than on a predefined
checklist and, therefore, affords a wider description of a
child’s faculties.15 It has demonstrated strong agreement
with the BSID, third edition (BSID-III) (interclass correlation coefficients 0·75–0·88, p<0·001 for all domains with
little to no bias on Bland Altman analysis); satisfactory
internal consistency (Cronbach’s alpha 0.56–0.81) and
good unidimensionality across subscales (Comparative
Fit Index=0.90; Tucker-Lewis Index=0 .94)16 and good
levels of inter-rater (k=0·70; 95% CI 0·47 to 0·88) and
test–retest reliability (k=0·79; 95% CI 0·48 to 0·96).15
The INTER-NDA is designed for use across socioeconomic groups and populations. Its operation manual,
standardisation protocol and forms are freely available at
www.intergrowth21.org.uk. The kit consists of common
household items encountered across the world. In all
study sites, the INTER-NDA was translated into the local
languages of the sites (Brazil: Brazilian Portuguese, India:
Marathi; Italy: Italian; Kenya: Kiswahili), using the WHO
Mental Health Initiative translation guidelines,17 which
included processes of cultural customisation, translation
and back translation.
Other outcome measures of neurodevelopment
To confirm the developmental normality of our cohort,
we assessed specific functional and developmental
outcomes of relevance by including three measurements
independent of the INTER-NDA: (1) visual acuity and
contrast sensitivity, measured on the Cardiff Tests18; (2)
3
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attention problems and emotional reactivity measured
on the respective subscales of the preschool CBCL19 and
(3) the age of achievement of six gross motor milestones
measured on the WHO’s checklist.20
The Cardiff Tests are validated and reliable measures
of binocular vision in children that are not influenced by
coexisting disturbances in language or cognition, and are
independent of cultural biases. Their norms have been
applied for clinical purposes.18 The operational manual
for their use in the INTERGROWTH-21st Project is available at https://www.intergrowth21.org.uk. Their administration takes 5 min. Visual acuity and contrast sensitivity
are measured in quick succession and taken together are
a more robust measure of the integrity and functioning of
the entire visual pathway than either test alone.21
The preschool version of the CBCL is a parent-rated
questionnaire used worldwide as a diagnostic screen for
behavioural and emotional problems in young children
(https://aseba.org/translations/).19 In the IFS of the
INTERGROWTH-21st Project, mothers completed questions relating to the attentional problems and emotional
reactivity CBCL scales.
The WHO Gross Motor milestones checklist consists
of the normative windows of achievement for six gross
motor milestones, developed from the WHO MGRS
cohort between 4 and 24 months of age.20 In the INTERGROWTH-21st Project, parents were asked to report the
age when they first observed or ‘never observed’ the milestones. The same information was collected from parents
at the 1-year and 2-year follow-up visits to evaluate the
consistency of the reported dates.11
Data management and statistics
The INTERGROWTH-21st Project neurodevelopmental
evaluation was supported by an electronic, tablet-
based data collection and management system (the
NeuroApp).15 This contained the INTER-NDA and vision
scoring forms, operation manuals, visual cues and integrated data quality checks to facilitate rapid collection of
high-quality data and to ensure their secure upload to the
project’s centralised and site-based data servers on which
rigorous monthly checks were performed.22
For the INTER-NDA, two standardisation evaluations
were carried out, in accordance with guidelines published
in the World Bank’s Toolkit for Examining Early Child
Development,3 to assess the ability of assessors to score and
administer the INTER-NDA. During the first evaluation,
assessors scored children’s skills on the INTER-NDA from
video recordings of four assessments performed by an
expert assessor. Inter-rater and test–retest reliability were
compared between assessors. At the second evaluation, an
expert observed assessors performing three assessments
each, and rated each assessor for their ability to administer the INTER-NDA correctly on a standardised protocol
adherence checklist (online supplementary information
S5). Protocol adherence scores were compared between
assessors. The results of these evaluations are presented
in online supplementary information S6.
4

The sample size considerations for this report have
been previously published and depended on pragmatic
considerations.23 In summary, as the present report is the
2-year follow-up of the initial FGLS cohort of pregnant
women, the total number of eligible children assessed at
2 years of age was therefore fixed. The initial sample size
estimations (approximately 500 fetuses per site) focused
on the precision and accuracy of the extreme centiles of
the complete population, that is, the 3rd or 97th centile
because they correspond closely to ±2 SD, and they are
the recommended cut-offs of the WHO Child Growth
Standards, which are used internationally to evaluate children of this age; however, in the present study, such estimations do not apply because of the different nature of
the hypothesis.23 In this component of the study, neurodevelopment was evaluated in an average of 261 children
per site (1307 children total) at 2 years of age. This sample
size was considered adequate to explore the predicted
small site-specific differences. Post hoc power calculations
showed that the study was sufficiently powered to observe
small differences among study sites (calculations for
INTER-NDA domains with power >0.99) and small effect
sizes for the between-group variances.23 For example, for
a between-group variance of 10% of the total variance
and a two-tail alpha of 0.05, the power is 0.84.
Summary statistics were calculated for birth, neonatal
and postnatal characteristics of children completing
the neurodevelopmental evaluation and compared with
those lost to follow-up. These characteristics include most
factors associated with poor child neurodevelopmental
outcomes during the first 2 years of life (online supplementary information S2). The analytical and statistical
strategy for the construction of the INTER-NDA centiles
is presented in figure 1. For all analyses, Stata V.15 software was used (StataCorp).
Data from the participating sites were pooled, following
the strategy recommended by WHO.7 We have previously reported striking similarities in the distribution of
the INTER-NDA domains among children from the five
sites.23 In summary, similar to the patterns observed in
linear growth from fetal life to childhood, the variability
in INTER-NDA scores between sites is far less (for most
domains <10%) than the total variability between individuals within a study site, justifying pooling the data to
construct international standards.23 24
Raw mean INTER-NDA domain scores (online supplementary information S716) were calculated and their
distributions explored. These showed important skewness
and (particularly) kurtosis. As 30 INTER-NDA items were
scored on a five-point scale, and six items were scored on
a three-point scale, raw domain scores were converted to
standardised scaled scores (online supplementary information S8).
To explore the low-risk profile of the cohort, centiles
for visual acuity (measured in logMAR) and contrast
sensitivity (measured in contrast per cent) were determined and compared with the Cardiff Tests’ established
norms.18 Attention problem and emotional reactivity
Fernandes M, et al. BMJ Open 2020;10:e035258. doi:10.1136/bmjopen-2019-035258
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Figure 1 Analytical and statistical strategy for the
construction of the International INTERGROWTH-21st Project
INTER-NDA standards. INTER-NDA, INTERGROWTH-21st
Neurodevelopment Assessment.

subscale scores were calculated using ASEBA-web software, and compared with the CBCL’s norms for group 1
societies.19 The proportion of children within the WHO
motor development windows of achievement was estimated as previously described.11
In addition, after other exclusions (figure 2), 28 of
1209 eligible children scored above the CBCL’s 97th
percentile threshold for clinical problems on the attentional problems and emotional reactivity CBCL subscales.
We compared INTER-
NDA centiles including and
excluding this group (online supplementary information S9). As the INTER-NDA centiles were marginally
lower on some domains when this group was included,
we decided to exclude these children from the normative
sample INTER-NDA sample in the construction of the
INTER-NDA domain standards.
As no transformation was identified that suited all
INTER-NDA domains, the Harrell-Davis distribution-free
estimator was used to estimate pooled centiles from the
standardised scaled scores.25 This estimator weights the
order statistics by the difference between two incomplete
beta functions. INTER-NDA scaled domain scores were
compared between boys and girls using the Wilcoxon
rank-sum test.
Fernandes M, et al. BMJ Open 2020;10:e035258. doi:10.1136/bmjopen-2019-035258

Figure 2 Participant flow for the INTERGROWTH-21st
Project Infant Follow-up Study cohort at 2 years of age.
CBCL, Child Behaviour Checklist; FGLS, Fetal Growth
Longitudinal Study; INTER-NDA, INTERGROWTH-21st
Neurodevelopment Assessment.

Patient and public involvement
Patients were not involved in developing plans for the
design of the study. Parents showed support for the
study through high and sustained follow-up rates in all
study sites. The INTERGROWTH-21st Project maintains
contact with parents in the cohort through newsletters,
webinars and blogs on its website, https://intergrowth21.
tghn.org/ and through Twitter (@intergrowth21st).
Results
The INTERGROWTH-21st Project IFS Study: INTER-NDA
normative cohort characteristics and overall health and
nutrition at 2 years of age
Population
Of the 1758 eligible children enrolled in the five participating sites, 1339 (76%) were assessed at 2 years of
age (figure 2). After exclusions (including 54 children
(3.1%) who were born at <37+0 weeks’ gestation and 28
children who scored at the threshold for clinical problems on the attentional problems and/or emotional
reactivity subscales of the CBCL), data from 1181 healthy
children (67% of those eligible) were pooled to construct
the international INTERGROWTH-21st Neurodevelopmental Standards. The study sites in Brazil, India,
5
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Table 1 Prenatal, perinatal and neonatal characteristics of children who completed the INTER-NDA in the INTERGROWTH21st Project compared with those lost to follow-up
Children contributing to
INTERGROWTH-21st international
INTER-NDA standards (n=1209)

Children lost to
follow-up (n=331)

Prenatal, perinatal and neonatal characteristics

Mean (SD) or number (%)

Mean (SD) or
number (%)

Maternal age at recruitment, years
Maternal body-mass-index, kg/m2

28.4 (3.8)
23.2 (3.0)

27.4 (4.3)
23.6 (2.8)

Multiple gestation

n=0 (0.0%)

n=0 (0.0%)

Chronic maternal illness

n=96 (8.1%)

n=26 (7.9)

Maternal infections (including HIV, rubella, syphilis, hepatitis B,
cytomegalovirus, toxoplasmosis, tuberculosis and malaria)

n=0 (0.0%)

n=1 (0.3)

Maternal haemoglobin (g/L)

124.0 (10.0)

124.0 (10.0)

Maternal malignancy

n=0 (0.0%)

n=0 (0.0%)

Maternal substance abuse (including alcohol) and smoking

n=0 (0.0%)

n=0 (0.0%)

Maternal use of teratogenic drugs during pregnancy

n=628 (53.2)

n=222 (67.1%)

Maternal prenatal anxiety and depression/mental stress

n=0 (0.0%)

n=0 (0.0%)

Maternal preeclampsia and eclampsia

n=10 (0.9%)

n=4 (1.2%)

Placental structural anomalies

n=0 (0.0%)

n=0 (0.0%)

Foetal growth restriction

n=67 (5.7%)

n=14 (4.2)

Gestational age at delivery, weeks*

39.6 (1.2)

39.3 (1.5)

Birth weight, kg*

3.2 (0.4)

3.2 (0.5)

Birth length, cm*

49.2 (1.8)

49.0 (2.1)

Head circumference at birth, cm*

34.0 (1.2)

34.0 (1.3)

Apgar at five min*

9.5 (0.6)

9.6 (0.7)

Age at hospital discharge, days†

3.0 (2.0 to 4.0)

2.0 (1.0 to 3.0)

Boys*

n=564 (47.8)

n=160 (48.3)

Hyperbilirubinaemia*

n=49 (4.1)

n=18 (5.5)

Respiratory distress syndrome*

n=16 (1.4)

n=7 (2.1)

Transient tachypnoea of the newborn*
Exclusive breastfeeding at hospital discharge*

n=11 (0.9)
n=1097 (93.0)

n=12 (3.6)
n=300 (90.9)

Data are mean (SD) or number (%) unless otherwise specified.
Missing data below 2% for all variables.
*Mean (SD).
†Median (IQR).
INTER-NDA, INTERGROWTH-21st Neurodevelopment Assessment.

Italy, Kenya and the UK respectively contributed 147
(12.2%), 305 (25.2%), 296 (24.5%), 301 (24.9%) and
160 (13.2%) children to the normative INTER-
NDA
cohort. A detailed description of the prenatal, birth, postnatal morbidity, growth and nutritional characteristics
of the cohort, during the first 2 years of life, has previously been published and is presented in tables 1 and 2.11
The comparison in sociodemographic, birth, health and
growth characteristics between the five sites that contributed to the normative INTER-NDA cohort, and the three
sites that did not, has also been previously published—
no significant differences were observed between the two
groups.11
6

The mean (±SD) age of both girls and boys at assessment was 24.8 (±1.6) months. Eighty-nine per cent of the
neurodevelopmental measures were obtained between
22 and 24 months of age, and 99.9% between 22 and 30
months. The baseline prenatal, perinatal and neonatal
characteristics were very similar across the five sites,23 and
with those children lost to follow-up (table 1).
Health, growth and nutritional outcomes from birth to 2 years
The cohort’s mean gestational age and weight at birth
were 39.6 (±1.2) weeks and 3.2 (±0.4) kg, respectively.11
The mean birth length and head circumference were
49.2 (±1.8) cm and 34.0 (+1.3) cm, respectively. Mean age
Fernandes M, et al. BMJ Open 2020;10:e035258. doi:10.1136/bmjopen-2019-035258
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Table 2 Postnatal morbidity between 1 and 2 years of age of children contributing to INTERGROWTH-21st international
INTER-NDA standards

Morbidity between 1 and 2 years of life

Children contributing to INTERGROWTH-21st
international INTER-NDA standards
(n=1209)

Hospitalised at least once
Total no of days hospitalised*

113 (9.4)
2 (1–3)

Any prescription provided by a healthcare practitioner

712 (59.1)

 Antibiotics (≥3 regimens)

142 (11.8)

 Iron/folic acid/vitamin B12/other vitamins

194 (16.1)

Up to date with local vaccination policies

1136 (94.4)

Otitis media/pneumonia/bronchiolitis
Parasitosis/diarrhoea/vomiting
Exanthema/skin disease
Urinary tract infection/pyelonephritis
Fever ≥3 days (≥3 episodes)

88 (7.3)
43 (3.6)
150 (12.5)
5 (0.4)
134 (11.1)

Other infections requiring antibiotics

40 (3.3)

Asthma

13 (1.1)

Gastro-oesophageal reflux
Cow’s milk protein allergy

3 (0.2)
8 (0.7)

Food allergies

13 (1.1)

Injury or trauma
Any condition requiring surgery

27 (2.2)
9 (0.7)

Data are number (%) unless otherwise specified.
Missing data below 2% for all variables.
*Median (IQR).
INTER-NDA, INTERGROWTH-21st Neurodevelopment Assessment.

at discharge from hospital, postbirth, was 3 (2-4) days.
At hospital discharge, 89% of the cohort was exclusively
breast milk fed.11 Exclusive breastfeeding was stopped at a
median of 5 months (IQR, 3–6 months) and (any) breast
feeding stopped entirely at a median of 12 months (IQR,
6–18 months). Detailed information on the nutritional
status of the cohort has been previously published.11
The overall postnatal morbidity of the cohort was low
(table 2): 9.4% of infants were hospitalised during the
second year of life with a median hospital stay of 2 days
(IQR 1–3 days). The most frequently morbidities reported
in outpatient clinics were exanthema/skin diseases, ≥3
episodes of fever lasting ≥3 days, and otitis media/lower-
tract respiratory infections.11 23 At 2 years of age, 92%,
90% and 91% of the cohort’s length, weight and head
circumference measures respectively were within the 3rd
and 97th centiles of the WHO Child Growth Standards.11
Developmental profile of the cohort on independent measures of
vision and development at 2 years
The visual acuity and contrast sensitivity centiles for our
cohort are presented in table 3. The cohort’s 50th centile
values for visual acuity and contrast sensitivity were 0.20
logMAR and 1.5%, respectively. Both are within the
Cardiff tests’ normative values for binocular visual acuity
Fernandes M, et al. BMJ Open 2020;10:e035258. doi:10.1136/bmjopen-2019-035258

in children aged 24–30 months.18 The visual acuity and
contrast sensitivity values were identical for boys and girls
across all centiles (table 3) suggesting no biological variability in these outcomes between sexes.
The cohort’s attentional problems and emotional reactivity scores at the 50th centile corresponded to CBCL
T-
scores of 53 and 50, respectively, that is, the 62nd
and <50th CBCL centiles. These values are below the
CBCL’s 93rd centile threshold for ‘borderline clinical
problems’.19 For these CBCL subscales, 28 (2.1%) FGLS
children scored above the CBCL’s cut-
off for clinical
problems (>97th centile). These children were excluded
from the INTER-NDA normative sample.
At 2 years of age, the cohort overlapped almost
perfectly with the WHO motor milestones at the 50th,
3rd and 97th centiles of the range for healthy term
infants.11 For length and head circumference, the
mean+SD z-score was 0.0±1.1 for both measures, and the
respective medians were at the 49th and 50th percentiles
of the WHO Child Growth Standards.11 For weight, the
mean±SD z-score was 0.2±1.1, and median was at the 58th
percentile. A detailed description of these characteristics
are presented elsewhere.11
7
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Table 3 Visual acuity and contrast sensitivity centiles, measured on the Cardiff tests, in the normative sample of the
International INTER-NDA standards
Pooled centiles (n=1209)

Girls (n=628)

Boys (n=581)

Visual acuity (logMAR)
 c10

0.3

0.3

0.3

 c25

0.2

0.2

0.2

 c50

0.2

0.2

0.2

 c75

0.1

0.1

0.1

 c90

0.1

0.1

0.1

 Median (IQR)

0.2 (0.1–0.2)

0.2 (0.1–0.2)

0.2 (0.1–0.2)

 c10

2.0

2.0

2.0

 c25

1.8

1.6

1.9

 c50

1.5

1.5

1.5

 c75

1.0

1.0

1.0

 c90
 Median (IQR)

1.0
1.5 (1.0–2.0)

1.0
1.5 (1.0–1.5)

1.0
1.5 (1.0–2.0)

P value

0.463

Contrast sensitivity (%)

0.303

*P value from Wilcoxon rank-sum test.
INTER-NDA, INTERGROWTH-21st Neurodevelopment Assessment.

International standards for the cognitive, motor, language and
behaviour domains of the INTER-NDA
The 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles
for the INTER-
NDA standardised (scaled) scores for
cognition, language, motor and behaviour domains for
healthy, well-nourished 2-year-old children are presented,
in table 4, for the pooled cohort. For all INTER-NDA
domains, except negative behaviour, higher scores reflect
better outcomes and the threshold for normality was
defined as ≥10th centile. For negative behaviour, where
lower scores reflect better outcomes, the threshold for
normality was defined as ≤90th centile. The thresholds
of normality for the INTER-NDA’s cognitive, fine motor,
gross motor, language and positive behaviour domains
are ≥38.5, ≥25.7, ≥51.7, ≥17.8 and ≥51.4, respectively.
The threshold for normality for the INTER-NDA’s negative behaviour domain is ≤50.0. To facilitate the easy

and rapid implementation of these standards, in clinical, community and research settings, for the identification of children scoring ≤10th and ≤3rd centile on
the INTER-NDA (≥90th and ≥97th centiles for negative
behaviour) who would benefit from urgent and routine
further assessment and/or specialist referral, respectively,
we have developed a neurodevelopmental chart that can
be printed or downloaded (figure 3).
INTER-
NDA domain scores were similar between
the cohort’s male and female children (online supplementary information S10). There was a trend towards
higher cognitive and language scores among girls, and
higher negative behaviour scores among boys (online
supplementary information S10); however, the clinical
and developmental implications of these differences are
unclear.

Table 4 The INTERGROWTH-21st Project international INTER-NDA standards for child development at 2 years of age
Pooled centiles (n=1181)
INTER-NDA domain

c3

c10

c25

c50

c75

c90

c97

Cognitive*
Fine motor*

27.4
17.5

38.5
25.7

62.2
74.2

79.5
91.4

88.8
100.0

92.6
100.0

99.6
100.0

Gross motor*

31.1

51.7

66.7

81.6

100.0

100.0

100.0

Language*

12.1

17.8

45.7

71.7

88.5

95.1

100.0

Positive behaviour*
Negative behaviour†

37.8
0.0

51.4
0.0

70.0
0.0

90.0
25.0

100.0
25.0

100.0
50.0

100.0
76.5

*For these domains, higher scores reflect better outcomes.
†For negative behaviour, lower scores reflect better outcomes.
INTER-NDA, INTERGROWTH-21st Neurodevelopment Assessment.
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Figure 3 The INTERGROWTH-21st Project international INTER-NDA standards for child development at 2 years of age.
INTER-NDA 3rd to 97th centile ranges for 2-year-old children are presented. These are based on scaled INTER-NDA
standardised domain scores. Scores falling in the yellow zone correspond to scores between the 10th and 3rd centiles; scores
in the orange zone correspond to scores <3rd centile. Clinical judgement should determine whether further developmental
assessment is warranted for children with scores in the yellow and orange zones, and the urgency of such referrals. INTER-
NDA, INTERGROWTH-21st Neurodevelopment Assessment.

Discussion
From this international, population-
based cohort of
optimally healthy and nourished children from Brazil,
India, Italy, Kenya and the UK (online supplementary
information S11 and S12); monitored from early pregnancy to 2 years of age, we have constructed international
prescriptive standards for cognitive, language, motor and
Fernandes M, et al. BMJ Open 2020;10:e035258. doi:10.1136/bmjopen-2019-035258

behavioural outcomes in 2-year-old children measured
on a rapid, comprehensive assessment—the INTER-NDA.
These centiles were constructed after excluding children born at <37 weeks gestation; those with significant/neurological morbidity, those whose mothers were
known to have a mental health diagnoses during pregnancy and those who scored above the threshold for
9
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clinical attentional and emotional reactivity problems on
the CBCL. We have confirmed the prenatal, perinatal,
neonatal and postnatal healthy and well-nourished status
of the normative INTER-
NDA cohort using multiple
measures during pregnancy, birth, 1 and 2 years of age;
and have confirmed, at 2 years of age, its low-risk profile or
adverse neurodevelopmental outcomes.11 The threshold
of normality for the INTER-NDA’s cognitive, fine motor,
gross motor, language and positive behaviour domains
is ≥38.5, ≥25.7, ≥51.7, ≥17.8 and ≥51.4, respectively. The
threshold for normality for the INTER-NDA’s negative
behaviour domain is ≤50.0. These centiles represent, to
our knowledge, the first endeavour to construct standards
for child developmental outcomes in this age group using
the WHO prescriptive methodology and an international
sampling frame. To facilitate the easy and rapid implementation of these standards in clinical, community and
research settings for the identification of children at risk
who would benefit from routine and urgent further assessment and specialist referral, respectively, we have developed a neurodevelopmental chart that can be printed or
downloaded (figure 3).
Strengths and limitations of this study
The strengths of the IFS Study of the INTERGROWTH-21st
Project include the population-based cohort design; the
use of the WHO recommended ‘prescriptive’ approach;
the international sampling frame; the inclusion of
rigorous data management, standardisation and quality
control procedures and the incorporation of independent measurements of specific functional and developmental domains (vision, attentional problems, emotional
reactivity and age of acquisition of key gross motor milestones) to confirm the satisfactory growth, health and
development of our cohort was confirmed prior to the
construction of these standards.11 In addition, we used
the INTER-NDA as the developmental measure of choice
to construct these standards (table 5). In online supplementary information S1 and S2, we present an overview
of the normative samples and thresholds for NDDs of
ten instruments commonly used to measure neurodevelopmental outcomes in 2-year-old children. Of these,
two tools (the Guide for Monitoring Child Development,
GMCD26 27 and the Caregiver-
reported Early Developmental Instruments, CREDI28) fulfil some of the WHO-
based methodological criteria for the construction of
child developmental standards (GMCD: criteria 1, 3
and 4; and CREDI: criteria 2 and 4). The INTER-NDA
fulfils 24 of the 26 criteria. Although a multidimensional
assessment is easy to implement and was designed for use
across population groups in high-income, middle-income
and low-
income settings.15 Despite an administration
time of 15 min, it has demonstrated good to acceptable
agreement with the BSID-III,16 and can be administered
reliably, in the field, by trained non-specialists (online
supplementary information S6).
The main limitation of our study was that the
INTER-NDA is restricted to the 2-year age group. We
10

selected 22–30 months as the time point for the key
developmental assessment of the entire study because
developmental markers at this age have been found to
be predictive of intelligence, school performance, adult
nutrition and human capital in high-income, middle-
income and low-income settings29–31; this age also corresponds to the end of Piaget’s sensorimotor stage.32 We
acknowledge that, while some authors prefer a wider age
range for population-based child developmental surveillance,3 the second birthday remains the earliest time
point at which a holistic snapshot of a child’s developmental repertoire can be captured reliably and parsimoniously at scale,15 while still within ‘the golden window of
opportunity for neurodevelopment rescue’—the first 3
years of life—when interventions are evidenced to yield
considerable benefits.33 Conversely, some may argue that
the 22–30 months age range is too broad in the context
of the rapidly developing nervous system. By evaluating
the performance of the INTER-NDA against the BSID-III
in children aged 22–30 months,16 we have provided
evidence that the INTER-
NDA is a valid and reliable
measure of child development in this age group. Nevertheless, the INTER-
NDA is a standardised screening
assessment and does not provide a clinical diagnosis.
Therefore, the possibility for misclassification must be
considered when interpreting the findings. A further
limitation is that three of the INTERGROWTH-21st
Project study sites (China, Oman and the USA) did
not participate in the neurodevelopmental evaluation.
While the inclusion of these sites might have increased
our overall sample size; as evidenced by the WHO MGRS
study, the representation of every country is not necessary for the construction of biological standards because
of the inherent prescriptive nature of the cohort.6 34
Our findings, published in 2014 and earlier this year,
confirmed that the growth and development of children
across different ancestries, geographies and cultures are
very similar from early pregnancy to 2 years of age, when
environmental constraints on their health and nutrition
are minimal, and justified the pooling of data across the
five populations for the construction of international
standards.23 24 An additional limitation of our study is the
exclusion of the detailed auditory and actigraphy data
from the analyses.
To address the question as to what limits should be
applied to determine thresholds of normal and non-
normal development,12 we were guided by other neurodevelopmental tools using centile ranks to stratify NDD
risk (online supplementary information S1). While many
of these define suboptimal development as below the
25th centile, we have presented evidence that most children in our cohort were developmentally normal for age.
Therefore, we selected a lower threshold (≥10th centile)
to define neurodevelopmental normality. Nevertheless,
we acknowledge that, in clinical practice, risk-threshold
determination may often take into consideration
other factors such as parental concerns and resource
allocation.12
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Yes
Yes

Yes
Yes
Moderately narrow age
range

Enjoyable for children to take (eg, interactive, colourful
materials)

Relatively easy to adapt to various cultures

Easy to use in low-resource settings, for example, not
requiring much material

Not too difficult to obtain or too expensive

Able to be used in a wide age range

22–30 months

See above

See Murray et al, for image of kit†; cost <GBP 120.00; no fee per use; manuals
and forms freely available at www.intergrowth21.org.uk

Adapted via cultural customisation session during training and currently in use in
12 countries (Brazil, India, Italy, Kenya, Pakistan, Thailand, South Africa, Mexico,
Grenada, Finland, Guatemala, Democratic Republic of Congo; www.inter-nda.
com)

 

Age range of items: 6–36 months‡

ICCs 0.74 and 0.88 (p<0.001) between BSID-III and INTER-NDA for cognitive,
language and motor domains; internal consistency 0.56–0.80†. Inter-rater
reliability: k = 0.70, 95% CI 0.47 to 0.88); test–retest reliability: k=0.79, 95% CI
0.48 to 0.96‡.

Additional details

Yes
Yes
Yes
Yes
Yes
Yes
Unknown
Yes
Yes
Yes
Yes
15 min

Results understood by health workers

Reliable

Valid

Acceptable to caregivers

Provides information that is relevant to primary care
providers

Information that can be used for referrals of early
intervention

Information that is useful for anticipatory guidance

Results understood by caregivers

Staff members have the expertise to answer questions

Access to application

Training involved

How long it takes to administer the tool

Continued

Time taken to train assessors in the INTER-NDA: 1 day for ≤3 assessors, 2 days
for 3–5 assessors, 3 days for 5–10 assessors
 

Freely accessible at www.intergrowth-21.org.uk

Session on maternal questions and responses included in training package.

 

 

Centiles

Centiles

 

See above

See above

Centiles

Fischer et al’s feasibility criteria for use of developmental screening tools at primary healthcare level in low-middle income settings§

Yes

Balanced in terms of no of items at the lower end to avoid
children with low scores

Yes

Does INTER-NDA fulfil
the criteria?

Evaluation of the INTER-NDA against pre-established feasibility criteria for use of an early child development assessment in a low-income and middle-income

World Bank Toolkit for Examining ECD*
Psychometrically adequate, valid and reliable

Table 5
setting

Open access

11

12
Minimal

Space

Normative sample drawn from a prospectively recruited sample of 2 years from
Brazil, India, Italy, Kenya and the UK with confirmed optimal nutritional, health
and developmental status during the first 1000 days of life.
Storage of kit and forms/table. See Murray et al, for image of kit.†

 

Results of comparison between field workers and specialists presented in online
supplementary table S6 and in text.

Sessions on cultural customisation and translation included in training

Cost of kit <GBP 120.00; no fee per use; manuals and assessment forms freely
available at www.intergrowth21.org.uk. Tablet/phone based data collection
application (INTER-NDA E-form) optional.

Cognition, language, fine and gross motor skills and behaviour (positive, negative
and global)‡

Additional details

*Fernald et al.
†Murray et al.16
‡Fernandes et al.15
§Fischer et al.4
BSID, Bayley Scales of Infant Development; ECD, early child development; ICCs, intraclass correlations; INTER-NDA, INTERGROWTH-21st Neurodevelopment Assessment.
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International references
available

Local norms available

Secondary education

Educational level of staff members
1

Yes

Minimal adaptation needed

How many staff members to administer the tool

Minimal

Cost of the tool

Does INTER-NDA fulfil
the criteria?
Yes

Continued

Cover multiple areas of child development

Table 5

Open access
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Context of the study
Measuring neurodevelopmental milestones during early
childhood at scale and comparing outcomes across populations are essential prerequisites for achieving the United
Nations Sustainable Development Goal (UN SDG) 4.2
(‘ensure that all girls and boys have access to quality early
child development, care and preprimary education so
that they are ready for primary education’). The international INTER-NDA standards presented here contribute
an important component to the care of young children:
a unique clinical tool for use across all healthcare systems
(table 5) to measure neurodevelopmental milestones
and associated behaviours in 2-year-old uniformly and at
scale, and to identify children at risk of NDDs who would
benefit from specialist referral and further investigation
(figure 3). It is hoped that these INTER-NDA standards,
complementing our published standards for fetal growth
and newborn size, and the WHO Child Growth Standards,
will (1) contribute to the attainment of the early child
development components of the UN SDGs and the WHO
survive, thrive, and transform goals of the Global Strategy
on Women’s, Children’s and Adolescents’ Health and
(2) provide a methodological template for the extension
of the construction of child developmental standards to
younger and older age groups.

Conclusion
From this international, population-
based cohort of
healthy and well-
nourished children, confirmed to
be at low-
risk of adverse health, growth and developmental outcomes during the first 2 years of life, we have
constructed the first international standards for cognition, language, motor skills and behaviour at 2 years of
age measured on the INTER-NDA. The use of standards
to measure early child development is superior to references because of their prescriptive nature and universal
applicability, in a manner similar to growth standards.
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